Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis

Clinical trial NCT07762833 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07762833
Sponsor: Galderma R&D
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis

Start date: 2026-09-28
Primary completion: 2027-09-28
Enrollment: 240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.